Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
AMINOADAMANTANES AS NMDA RECEPTOR ANTAGONISTS AND ANTIPARKINSONIAN AGENTS - PRECLINICAL STUDIES
Autore:
DANYSZ W; PARSONS CG; KORNHUBER J; SCHMIDT WJ; QUACK G;
Indirizzi:
MERZ & CO,DEPT PHARMACOL,ECKENHEIMER LANDSTR 100-104 D-60318 FRANKFURT GERMANY UNIV GOTTINGEN,DEPT PSYCHIAT D-3400 GOTTINGEN GERMANY UNIV TUBINGEN,INST ZOOL,DEPT NEUROPHARMACOL TUBINGEN GERMANY
Titolo Testata:
Neuroscience and biobehavioral reviews
fascicolo: 4, volume: 21, anno: 1997,
pagine: 455 - 468
SICI:
0149-7634(1997)21:4<455:AANRAA>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
METHYL-D-ASPARTATE; MONOAMINE-DEPLETED RATS; EXCITATORY AMINO-ACIDS; HUMAN FRONTAL-CORTEX; NEURONAL CELL-LINE; PARKINSONS-DISEASE; BASAL GANGLIA; NEUROPROTECTIVE PROPERTIES; DOPAMINERGIC TRANSMISSION; AMANTADINE INCREASES;
Keywords:
MEMANTINE; AMANTADINE; NMDA RECEPTORS; PARKINSONS DISEASE; ANIMAL MODELS; NEUROPROTECTION; MECHANISM OF ACTION; SERUM LEVELS; BRAIN LEVELS; REVIEW;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
151
Recensione:
Indirizzi per estratti:
Citazione:
W. Danysz et al., "AMINOADAMANTANES AS NMDA RECEPTOR ANTAGONISTS AND ANTIPARKINSONIAN AGENTS - PRECLINICAL STUDIES", Neuroscience and biobehavioral reviews, 21(4), 1997, pp. 455-468

Abstract

Aminoadamantanes such as 1-aminoadamantane (amantadine) and 1-amino-3,5-dimethyladamantane (memantine) are N-methyl-D-aspartate (NMDA) receptor antagonists which show antiparkinsonian-like activity in animal models and in Parkinson's patients. The issue of whether NMDA antagonism plays a role in the symptomatological antiparkinsonian activity of amantadine and memantine is addressed by comparing: behaviourally effective doses, serum/brain levels, and their potency as NMDA receptor antagonists. In the case of memantine, blockade of NMDA receptors is probably the only mechanism responsible for antiparkinsonian activity, whereas for amantadine the situation is clearly far more complex. There are a number of differences between memantine and amantadine both in vitro and in vivo, and although NMDA receptor antagonism certainly participates in the antiparkinsonian activity of amantadine, other effects,some of which are elusive, also play a role. Moreover, it has been suggested that the pathomechanism of Parkinson's disease involves excitotoxic processes and that treatment with NMDA receptor antagonists might also slow the progression of neurodegeneration. If this claim is true, such an effect could be achieved with amantadine and memantine which show neuroprotective activity in animals al therapeutically relevantdoses. (C) 1997 Elsevier Science Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 23:21:13